Liva Healthcare secures €24.5m funding - led by Verlinvest - to drive European leadership in digital chronic disease prevention and management
6.1.2021 10:00:00 EET | Business Wire | Press release
Liva Healthcare (“Liva”), a European market leader in scalable digital health coaching, has secured a new funding round of EUR 24.5 million, led by Verlinvest, the go-to investor for mission-driven entrepreneurs and category-defining global consumer brands. The investment will enable Liva to strengthen its position as a European leader in digital health and lifestyle coaching for chronic disease prevention and management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005831/en/
Liva Healthcare secures €24.5m funding - led by Verlinvest - to drive European leadership in digital chronic disease prevention and management (Photo: Business Wire)
Liva is a health tech company headquartered in Copenhagen and London with the mission to improve the lives of people at risk of, or living with, chronic conditions such as Type 2 diabetes, obesity, and heart diseases by driving positive behavioural change. Liva blends scalable health coaching focused on personal human relationships with an intuitive and user-friendly interface. Liva was founded in 2015 by the team behind independent health information portal NetDoctor.com.
The on-going Covid-19 pandemic has led to a significant shift in acceptance of remote healthcare by European consumers. This shift in acceptance and the subsequent patient behaviour has given Liva a significant increase in interest from public healthcare providers and life science companies in 2020.
Liva is used by clients such as Novo Nordisk, AXA Health, Amgen, City of Copenhagen, Bupa Australia and several other key players in public healthcare, insurance and life science industries globally. Liva is also a partner to NHS England on its world-leading National Diabetes Prevention Programme. Liva is currently operational in Britain, Australia, Ireland, Holland, Belgium, Denmark, Sweden, and Finland with operations currently being setup in Germany and Switzerland.
“This new funding, from one of Europe’s strongest purpose-led, consumer growth investors, will substantially accelerate our expansion in core European markets,” says André Sode, CEO of Liva Healthcare. “COVID-19 has demonstrated how effective remote digital health solutions can be. With healthcare providers around the world looking for scalable solutions to combat the rise in diabetes and obesity, we are ideally placed to support and have experienced a significant increase in interest as a result.”
“This investment represents a major new entry into digital health for Verlinvest, where technology is fuelling consumer revolutions,” says Simone Sallustio, Executive Director at Verlinvest. “Digital healthcare has been vital in getting treatment to patients during the pandemic and this trend will continue as effective virtual programmes give people more flexible healthcare options. Liva’s advanced technology and proven clinical outcomes set it apart from its competitors. In this exciting and rapidly evolving space, Liva’s experience and established partnerships represent a strategic choice for Verlinvest.”
About Liva Healthcare:
Liva Healthcare is a leading provider of scalable digital health coaching, delivering human-centric coaching through an advanced app to help people prevent and manage obesity, prediabetes, type 2 diabetes and cardiovascular diseases.
For more information: livahealthcare.com, LinkedIn and Twitter.
About Verlinvest:
Verlinvest is a privately-owned family investment company based in Brussels with offices in New York, London, and Singapore.
For more information: www.verlinvest.com and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005831/en/
Contact information
Lewis Oakley
+44-7767-887-035
lewis@milkandhoneypr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 12:00:00 EET | Press release
Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311319953/en/ Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler
NTT DATA Unveils NVIDIA-Powered Enterprise AI Factories to Support Secure AI Adoption and Help Clients Drive Measurable ROI11.3.2026 12:00:00 EET | Press release
NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI. NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to end. The company’s new enterprise AI factories integrate the NVIDIA AI infrastructure—combining GPU-accelerated computing and high-performance networking—with NVIDIA AI Enterprise software, including NVIDIA NIM microservices, to deliver high‑throughput, low‑latency AI that can be deployed consi
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health11.3.2026 11:00:00 EET | Press release
Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311389622/en/ parodontax, Haleon's clinically proven gum health brand, is expanding across China As part of this shift, more consumers are embedding preventative oral care into their daily self-care routines, and demand for premium, science-backed solutions is accelerating at a rapid pace. This investment strengthens Haleon’s local manufacturing footprint and positions the business to capture
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 10:00:00 EET | Press release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage11.3.2026 09:40:00 EET | Press release
1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform. The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two biggest massive IoT network specialists — 1NCE, the biggest private IoT network in the cloud and Netmore, the largest LoRaWAN network and platform provider in the world. 1NCE’s software and connectivity platform has become a new industry standard. Working together to support their respective customer bases with both cellular and LoRaWAN technology delivers a powerful layer of redundancy to cover the hardest to re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom